Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Integra to buy J&J's...

    Integra to buy J&J's Codman neurosurgery business for $1.05 billion

    Written by supriya kashyap kashyap Published On 2017-02-18T09:23:49+05:30  |  Updated On 18 Feb 2017 9:23 AM IST
    Integra to buy J&Js Codman neurosurgery business for $1.05 billion

    Medical device maker Integra LifeSciences Holdings Corp said it would buy Johnson & Johnson's Codman neurosurgery business for $1.05 billion in cash, to expand its presence outside the United States.


    Integra, which makes products used in neurosurgery, reconstruction, wound and dental care, made a "binding offer" for the Codman business, which will bolster its pipeline of offerings for tissue ablation, spinal cord repair and cranial stabilization.


    The companies will finalize the deal after receiving the green light from various works councils and regulators, a J&J spokeswoman told Reuters, adding that the deal would close in the fourth quarter, if approved.


    Integra said its adjusted earnings per share would increase by at least 22 cents in the first full year after closing and rise thereafter.


    The deal would enable the company to generate 30 percent or more of sales from international markets, Integra executives said on a conference call.


    However, Integra expects some disruption in the Codman business in the first year following the purchase, but forecast the business would grow 3-6 percent in the longer term.


    The Codman neurosurgery business, which is part of J&J's DePuy Synthes unit and markets devices for use in neuro-critical care and electrosurgery, generated sales of about $370 million in 2016.


    The deal excludes Codman's neurovascular and drug delivery businesses, J&J said.


    The U.S. healthcare giant, which is buying Swiss biotech company Actelion Ltd in a $30 billion deal, said last month it was reviewing strategic options for some of its diabetes care businesses.


    Integra's shares rose as much as 6 percent to $45.87 in morning trade, while J&J's stock was marginally up.


    As of Tuesday's close, Integra's shares had gained about 56 percent in the past 12 months, while J&J's stock had risen 14 percent.


    If the proposed deal is not closed, DePuy is entitled to receive a termination fee of $60 million, according to a regulatory filing.


    Plainsboro, New Jersey-based Integra, which hopes the transaction will accelerate its path to generate $2 billion in revenue, said it has obtained committed financing from BofA Merrill Lynch and JP Morgan.


    BofA Merrill Lynch is serving as Integra's financial adviser, while Latham & Watkins LLP is its legal adviser.

    ActelionCodman neurosurgeryIntegra LifeSciences HoldingsJ&JJohnson and Johnsonmedical deviceneurosurgery
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok